Heartland Advisors Inc. Purchases Shares of 214,777 Envista Holdings Co. (NYSE:NVST)

Heartland Advisors Inc. acquired a new position in shares of Envista Holdings Co. (NYSE:NVST - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 214,777 shares of the company's stock, valued at approximately $4,143,000. Heartland Advisors Inc. owned about 0.12% of Envista at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in NVST. Iron Triangle Partners LP acquired a new stake in shares of Envista in the 3rd quarter worth about $43,262,000. Norges Bank bought a new position in shares of Envista in the fourth quarter valued at approximately $38,052,000. Point72 Asset Management L.P. purchased a new position in shares of Envista during the third quarter valued at approximately $37,559,000. Polar Asset Management Partners Inc. raised its position in Envista by 375.6% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company's stock valued at $29,586,000 after buying an additional 1,182,450 shares during the last quarter. Finally, Pzena Investment Management LLC bought a new position in Envista during the 4th quarter valued at $16,979,000.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Piper Sandler increased their target price on shares of Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Morgan Stanley dropped their target price on shares of Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Wells Fargo & Company set a $19.00 price target on Envista in a report on Saturday, March 8th. Finally, New Street Research set a $19.00 target price on Envista in a research report on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Envista presently has an average rating of "Hold" and a consensus target price of $20.18.

Remove Ads

Envista Stock Performance

Envista stock traded up $0.39 during mid-day trading on Wednesday, reaching $17.49. The company's stock had a trading volume of 2,227,037 shares, compared to its average volume of 2,431,449. The firm's fifty day moving average price is $19.47 and its two-hundred day moving average price is $19.59. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista Holdings Co. has a 12-month low of $15.15 and a 12-month high of $23.00. The company has a market capitalization of $3.01 billion, a P/E ratio of -2.69, a PEG ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Sell-side analysts predict that Envista Holdings Co. will post 1 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.